Curative radiation for orbital MZL: How much? Journal Article
| Author: | Yahalom, J. |
| Article Title: | Curative radiation for orbital MZL: How much? |
| Abstract: | In this issue of Blood, Desai et al report a large retrospective analysis from the University of Miami including 182 patients with primary ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphoma (orbital marginal zone lymphoma [MZL]).1 Most were at an early stage (82%), and 76% were treated successfully with orbital irradiation. Treatment and follow-up data spanned 31 years. This study reaffirms the excellent long-term control of orbital MZL with localized radiation therapy (RT; complete remission [CR] rate >97%); only 3 deaths were attributed to lymphoma, and 2 of those occurred following systemic transformation. © 2017 by The American Society of Hematology. |
| Keywords: | cancer survival; overall survival; disease course; review; cancer recurrence; intensity modulated radiation therapy; treatment planning; cancer radiotherapy; radiation dose; outcome assessment; follow up; prospective study; progression free survival; relapse; risk factor; risk assessment; cause of death; electron therapy; biological activity; tumor cell; long term care; remission; retinopathy; prematurity; radiation dose distribution; marginal zone lymphoma; orbit tumor; lymph node irradiation; recurrence free survival; radiobiology; eradication therapy; proton therapy; neovascular glaucoma; lacrimal gland; cornea ulcer; conjunctiva; human; priority journal; optic nerve atrophy; patient risk; ocular adnexal mucosa associated lymphoid tissue lymphoma |
| Journal Title: | Blood |
| Volume: | 129 |
| Issue: | 3 |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2017-01-19 |
| Start Page: | 270 |
| End Page: | 271 |
| Language: | English |
| DOI: | 10.1182/blood-2016-11-749176 |
| PROVIDER: | scopus |
| PUBMED: | 28104673 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 2 January 2018 -- Source: Scopus |
